Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Public ClinicalTrials.gov record NCT07098299. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Dose-escalation and Metabolomics Study of Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to evaluate the safety of Metformin alone and in combination with chemotherapy or immunotherapy in patients with solid tumor cancers. The main questions it aims to answer are: * what are the toxicities of metformin at multiple dose levels * what is the maximum tolerated dose of Metformin in combination with chemotherapy or immunotherapy Participants enrolled will be treated with standard of care chemotherapy and/or immunotherapy in accordance to their disease/stage. In addition, participants will take Metformin alone for 14 days in between the first cycle of chemotherapy and the second cycle of chemotherapy to determine tolerability to the Metformin. Participants will then take Metformin daily in combination with the standard of care chemotherapy and/or Immunotherapy from cycle 2 onwards.
Study identification
- NCT ID
- NCT07098299
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 18, 2025 (Actual)
- Primary completion
- Jul 7, 2027 (Estimated)
- Completion
- Jul 7, 2028 (Estimated)
- Last update posted
- Jul 24, 2026
2025 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 1
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Karmanos Cancer Institute at McLaren Bay Region | Bay City | Michigan | 48706 | Recruiting |
| Karmanos Cancer Institute at McLaren Clarkston | Clarkston | Michigan | 48346 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Karmanos Cancer Institute at McLaren Flint | Flint | Michigan | 48532 | Recruiting |
| Karmanos Cancer Institute at McLaren Greater Lansing | Lansing | Michigan | 48910 | Recruiting |
| Karmanos Cancer Institute at McLaren Lapeer Region | Lapeer | Michigan | 48466 | Recruiting |
| Karmanos Cancer Institute at McLaren Macomb | Macomb | Michigan | 48043 | Recruiting |
| Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center | Mount Pleasant | Michigan | 48858 | Recruiting |
| Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey | Petoskey | Michigan | 49770 | Recruiting |
| Karmanos Cancer Institute at McLaren Port Huron | Port Huron | Michigan | 48060 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07098299, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 24, 2026 · Synced Oct 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07098299 live on ClinicalTrials.gov.